Skip to main content
. 2021 Sep 14;13(9):1466. doi: 10.3390/pharmaceutics13091466

Figure 2.

Figure 2

Implications of pharmacokinetics (including CYP2D6 genetic polymorphism and CYP2D6 drug–drug interactions) and pharmacodynamics as determinants of interindividual difference in drug response to oxycodone and oxymorphone. CYP2D6: cytochrome P450 2D6; DDI: drug–drug interaction; BBB: blood–brain barrier. Created with Biorender.com (access date: 10 May 2021).